Regulus Therapeutics Inc (RGLS) Holdings Trimmed by Candriam Luxembourg S.C.A.

Candriam Luxembourg S.C.A. lessened its stake in shares of Regulus Therapeutics Inc (NASDAQ:RGLS) by 16.7% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 500,000 shares of the biopharmaceutical company’s stock after selling 100,000 shares during the quarter. Candriam Luxembourg S.C.A.’s holdings in Regulus Therapeutics were worth $520,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Royal Bank of Canada grew its holdings in Regulus Therapeutics by 12.1% during the 2nd quarter. Royal Bank of Canada now owns 184,040 shares of the biopharmaceutical company’s stock valued at $182,000 after buying an additional 19,934 shares in the last quarter. FMR LLC grew its holdings in Regulus Therapeutics by 0.5% during the 2nd quarter. FMR LLC now owns 7,977,349 shares of the biopharmaceutical company’s stock valued at $7,862,000 after buying an additional 37,489 shares in the last quarter. Victory Capital Management Inc. grew its holdings in Regulus Therapeutics by 18.2% during the 4th quarter. Victory Capital Management Inc. now owns 327,770 shares of the biopharmaceutical company’s stock valued at $341,000 after buying an additional 50,530 shares in the last quarter. GSA Capital Partners LLP grew its holdings in Regulus Therapeutics by 44.8% during the 3rd quarter. GSA Capital Partners LLP now owns 203,815 shares of the biopharmaceutical company’s stock valued at $255,000 after buying an additional 63,100 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its holdings in Regulus Therapeutics by 189.1% during the 2nd quarter. Goldman Sachs Group Inc. now owns 368,285 shares of the biopharmaceutical company’s stock valued at $363,000 after buying an additional 240,890 shares in the last quarter. 57.83% of the stock is owned by institutional investors and hedge funds.

RGLS has been the subject of a number of recent analyst reports. Zacks Investment Research raised Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 target price for the company in a report on Wednesday, January 24th. Needham & Company LLC reiterated a “hold” rating on shares of Regulus Therapeutics in a research report on Tuesday, November 14th. Chardan Capital reiterated a “neutral” rating on shares of Regulus Therapeutics in a research report on Tuesday, January 16th. Wedbush reiterated an “outperform” rating and set a $4.00 price target on shares of Regulus Therapeutics in a research report on Monday, December 11th. Finally, Leerink Swann began coverage on Regulus Therapeutics in a research report on Friday, January 5th. They set an “outperform” rating and a $2.00 price target for the company. One analyst has rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $2.50.

Shares of Regulus Therapeutics Inc (RGLS) opened at $1.16 on Friday. The stock has a market capitalization of $116.57, a PE ratio of -0.87 and a beta of 1.72. The company has a current ratio of 6.77, a quick ratio of 6.77 and a debt-to-equity ratio of 0.41. Regulus Therapeutics Inc has a 12-month low of $0.79 and a 12-month high of $1.95.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The correct version of this news story can be read at https://www.thelincolnianonline.com/2018/02/24/regulus-therapeutics-inc-rgls-holdings-trimmed-by-candriam-luxembourg-s-c-a.html.

Regulus Therapeutics Profile

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Want to see what other hedge funds are holding RGLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regulus Therapeutics Inc (NASDAQ:RGLS).

Institutional Ownership by Quarter for Regulus Therapeutics (NASDAQ:RGLS)

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply